White Papers / Tech Papers

Why is Big Pharma Increasingly Adopting 505(b)(2)?

USFDA 505(b)(2) pathway submissions (“(b)(2)s”) can be advantageous because they offer the potential for the accelerated approval of patient-centric medicines.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters